• Island Pharmaceuticals Ltd (ASX: ILA) presents at Gold Coast Investment Showcase
• Highlights Galidesivir's progress under FDA Animal Rule
• Expanded CRADA with USAMRIID for dose optimization study
• Upcoming investor webinar on 12 June 2026
• Discussion on biodefense preparedness and Galidesivir's potential

Island Pharmaceuticals Ltd (ASX: ILA) is set to present at the Gold Coast Investment Showcase from 11-12 June 2026, and will hold an investor webinar on 12 June 2026. The presentation emphasizes the company's momentum in regulatory, clinical, and manufacturing initiatives for its antiviral drug Galidesivir, including its progression under the FDA Animal Rule pathway, an expanded Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID), and the commencement of Good Manufacturing Practice (GMP) manufacturing. These initiatives aim to de-risk the Galidesivir program and support multiple value drivers, including a Tropical Disease Priority Review Voucher and future government procurement opportunities. The presentation also discusses the growing global focus on biodefense preparedness, the limitations of existing filovirus countermeasures, and Galidesivir's potential as a broad-spectrum antiviral capable of addressing multiple high-consequence viral threats.